FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ferrante Karen Jean</u>					2. Issuer Name and Ticker or Trading Symbol Unum Therapeutics Inc. [UMRX]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
						-						V Directo	r	10% O	wner	
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							Officer below)	(give title	Other (sbelow)	specify	
C/O UNUM THERAPEUTICS INC.				1	10/01/2018											
200 CAMBRIDGE PARK DRIVE, SUITE 3100				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street)											Line	,	led by One Re	aartina Daraa	_	
CAMBR	IDGE 1	MA	02140									_	led by More th	•	- 1	
(City)	(State)	(Zip)													
		Tal	ole I - Non-E	Derivati	ve Se	curities	Ac	quired, Di	sposed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Date)				ate	Execution if any			xecution Date, Transaction				5. Amour Securitie Beneficia Owned F	es Form ally (D) o following (I) (Ir	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code				Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) f ive	Execution Date,	Code	saction (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$10.37	10/01/2018		A		1,769 ⁽¹⁾		(2)	10/01/2028	Common Stock	1,769	\$6.22	1,769	D		

Explanation of Responses:

1. The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

2. This option is fully vested at time of grant.

Remarks:

/s/ Amoli Pandya, as Attorney-

10/03/2018

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.